Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 726

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes

Open access
Moran, Antoinette, Brunzell, Carol, Cohen, Richard C., Katz, Marcia, Marshall, Bruce C., Onady, Gary, Robinson, Karen A., Sabadosa, Kathryn A., Stecenko, Arlene, Slovis, Bonnie, the CFRD Guidelines Committee·2010·Diabetes Care

Abstract

ystic fibrosis-related diabetes (CFRD) is the most common comorbidity in people with cystic fibrosis (CF), occurring in ϳ20% of adolescents and 40 -50% of adults (1).While it shares features of type 1 and type 2 diabetes, CFRD is a distinct clinical entity.It is primarily caused by insulin insufficiency, although fluctuating levels of insulin resistance related to acute and chronic illness also play a role.The additional diagnosis of CFRD has a negative impact on pulmonary function and survival in CF, and this risk disproportionately affects women (2-4).In contrast to patients with other types of diabetes, there are no documented cases of death from atherosclerotic vascular disease in patients with CFRD, despite the fact that some now live into their sixth and seventh decades.These guidelines are the result of a joint effort between the Cystic Fibrosis Foundation (CFF), the American Diabetes Association (ADA), and the Pediatric Endocrine Society (PES).They are intended for use by CF patients, their care partners, and health care professionals and include recommendations for screening, diagnosis, and medical management of CFRD.This report focuses on aspects of care unique to CFRD.A comprehensive summary of recommendations for all people with diabetes can be found in the ADA Standards of Medical Care, published annually in the January supplement to Diabetes Care (5).METHODS -In 2009, CFF in collaboration with ADA and PES convened a committee of CF and diabetes experts to update clinical care guidelines for CFRD.Investigators at Johns Hopkins University conducted evidence reviews on relevant clinical questions identified by the guidelines committee.The reviews were provided to the committee to use in developing recommendations.Where possible, the evidence for each recommendation was considered and graded by the committee using the ADA (5) and the U.S. Preventive Services Task Force (USP-STF) (6) grading systems (Table 1).Recommendations from existing published guidelines were used when available and appropriate, and these are indicated as consensus statements.The committee also made consensus recommendations for topics not included in the evidence reviews or for which limited evidence was available in the literature.Recommendations will be updated as warranted by new evidence, and the guidelines will be reviewed 3 years after release date to determine if an update is needed.A summary of the committee's recommendations is presented in Table 2.SCREENING -CFRD is often clinically silent.In other populations, the primary consequences of unrecognized diabetes are macrovascular and microvascular disease.In CF, the nutritional and pulmonary consequences of diabetes are of greater concern.CFRD is associated with weight loss, protein catabolism, lung function decline, and increased mortality (2,3,7-17), and thus regular screening is warranted. Screening tests for CFRDAlthough hemoglobin A1C (A1C) may become the standard screening test for type 2 diabetes (5), the committee concluded that it is not sufficiently sensitive for diagnosis of CFRD and thus should not be used as a screening test.Eight studies were identified that assessed A1C as a screening test in this population (7,18 -24).The authors of one prospective cohort study of 62 participants with CF and 107 healthy control subjects reported that A1C levels were higher in the CF group than among the control subjects, leading them to suggest that the use of A1C was appropriate (18).However, six studies (including two prospective cohort studies [7,21], two cross-sectional studies [19,20], one case-control study [23], and one case series [22[) with a total of 477 participants demonstrated low degrees of correlation between A1C and glucose tolerance status (7,19 -23).Additionally, a cross-sectional study of 191 participants

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc10-1768

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Research works printed but not linked: 10

  1. Peraldo, 1998, Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients, Horm Res, 49, 65
  2. Hunkert, 1999, Potential impact of HbA1c determination on clinical decision making in patients with cystic fibrosis-related diabetes (Letter), Diabetes Care, 22, 1008, 10.2337/diacare.22.6.1008 · doi:10.2337/diacare.22.6.1008
  3. Goss, 2003, The effect of pregnancy on survival in women with cystic fibrosis, Chest, 124, 1460, 10.1378/chest.124.4.1460 · doi:10.1378/chest.124.4.1460
  4. Mekeel, 2007, Combined en bloc liver pancreas transplantation for children with CF, Liver Transpl, 13, 406, 10.1002/lt.21070 · doi:10.1002/lt.21070
  5. Madden, 1992, Intermediate-term results of heart-lung transplantation for cystic fibrosis, Lancet, 339, 1583, 10.1016/0140-6736(92)91842-V · doi:10.1016/0140-6736(92)91842-v
  6. Yung, 1998, Diabetic retinopathy in adult patients with cystic fibrosis-related diabetes, Respir Med, 92, 871, 10.1016/S0954-6111(98)90390-0 · doi:10.1016/s0954-6111(98)90390-0
  7. Hayes, 1994, Mangement dilemmas in the individual with cystic fibrosis and diabetes, J Am Diet Assoc, 94, 78, 10.1016/0002-8223(94)92046-X · doi:10.1016/0002-8223(94)92046-x
  8. Franzese, 2005, Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes?, Diabetes Care, 28, 2333, 10.2337/diacare.28.9.2333 · doi:10.2337/diacare.28.9.2333
  9. Brunzell, 2002, CFRD and abnormal glucose tolerance: overview and medical nutrition therapy, Diabetes Spectr, 15, 124, 10.2337/diaspect.15.2.124 · doi:10.2337/diaspect.15.2.124
  10. Sullivan, 1989, Diabetic microangiopathy in patients with cystic fibrosis, Pediatrics, 84, 642, 10.1542/peds.84.4.642 · doi:10.1542/peds.84.4.642

Cited by

See all 726

Metadata

Authors
Moran, A., Brunzell, C., Cohen, R. C., Katz, M., Marshall, B. C., Onady, G., Robinson, K. A., Sabadosa, K. A., Stecenko, A., Slovis, B., & the CFRD Guidelines Committee
Venue
Diabetes Care
Published
2010-12-01
Volume
33
Issue
12
Pages
2697-2708
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2157745572
Cited by
726
References
62
FWCI
20.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes. https://app.cochat.ai/papers/10.2337/dc10-1768
The paper
Moran, A., Brunzell, C., Cohen, R. C., Katz, M., Marshall, B. C., Onady, G., Robinson, K. A., Sabadosa, K. A., Stecenko, A., Slovis, B., & the CFRD Guidelines Committee. (2010). Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes. Diabetes Care. https://doi.org/10.2337/dc10-1768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.